MK 2060
Alternative Names: MK-2060Latest Information Update: 29 Oct 2024
At a glance
- Originator Merck Sharp & Dohme
- Class Anticoagulants; Antithrombotics; Monoclonal antibodies; Urologics
- Mechanism of Action Factor XI inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Thrombosis
- Phase I Renal failure
Most Recent Events
- 15 Oct 2024 Merck Sharp & Dohme initiates phase I safety, pharmacokinetics, and pharmacodynamics trial (In volunteers (IV, infusion) in the US (NCT06582602)
- 03 Sep 2024 Merck Sharp & Dohme plans a phase I safety, pharmacokinetics, and pharmacodynamics trial in healthy subjects (IV, infusion, ) in September 2024 (NCT06582602)
- 15 Feb 2024 Merck Sharp & Dohme completes a phase-I trial in Renal failure (In adults, In the elderly) in Japan (NCT05769595),